
Timeline of Cancer Immunotherapy Approvals by FDA
08/29/2010 - Dendreon Corporation - Provenge - Advanced prostate cancer
03/28/2011 - Bristol-Myers Squibb - Yervoy - Advanced melanoma
09/04/2014 - Merck - Keytruda - Previously treated advanced melanoma
12/03/2014 - Amgen - Blincyto - Philadelphia negative precursor B-cell ALL
12/22/2014 - Bristol-Myers Squibb - Opdivo - Previously treated advanced melanoma
03/04/2015 - Bristol-Myers Squibb - Opdivo - Previously treated advanced squamous NSCLC
10/01/2015 - Bristol-Myers Squibb - Opdivo+Yervoy - BRAF V600 wild-type melanoma
10/02/2015 - Merck - Keytruda - Previously treated advanced NSCLC
10/09/2015 - Bristol-Myers Squibb - Opdivo - Previously treated advanced non-squamous NSCLC
10/27/2015 - Amgen - Imlygic - Melanoma lesions in the skin and lymph nodes
10/28/2015 - Bristol-Myers Squibb - Yervoy - To lower the risk that melanoma will return after surgery
11/23/2015 - Bristol-Myers Squibb - Opdivo - Previously treated advanced renal cell carcinoma
12/18/2015 - Merck - Keytruda - First-line treatment for advanced melanoma
01/23/2016 - Bristol-Myers Squibb - Opdivo+Yervoy - Metastatic melanoma across BRAF status
05/17/2016 - Bristol-Myers Squibb - Opdivo - Classical Hodgkin lymphoma post auto-HSCT
05/18/2016 - Roche - Tecentriq - Previously treated advanced urothelial carcinoma
08/05/2016 - Merck - Keytruda - Recurrent or metastatic head and neck squamous cell carcinoma
09/01/2016 - Amgen - Blincyto - Pediatric Philadelphia negative r/r precursor B-cell ALL
10/18/2016 - Roche - Tecentriq - Advanced NSCLC for patients with EGFR or ALK abnormalities
10/24/2016 - Merck - Keytruda - First-line NSCLC for patients who have high PD-L1 expression
11/10/2016 - Bristol-Myers Squibb - Opdivo - Recurrent or metastatic H&N squamous cell carcinoma
02/02/2017 - Bristol-Myers Squibb - Opdivo - Previously treated advanced urothelial carcinoma
03/15/2017 - Merck - Keytruda - Refractory classical Hodgkin lymphoma
04/17/2017 - Roche - Tecentriq - As initial treatment for certain advanced urothelial carcinoma patients
03/23/2017 - Pfizer - Bavencio - Metastatic Merkel cell carcinoma
05/01/2017 - AstraZeneca - Imfinzi - Previously treated advanced urothelial carcinoma
05/09/2017 - Pfizer - Bavencio - Previously treated advanced urothelial carcinoma
05/10/2017 - Merck - Keytruda+Chemo - First-line NSCLC irrespective of PD-L1 expression
05/18/2017 - Merck - Keytruda - Previously treated advanced urothelial carcinoma
05/18/2017 - Merck - Keytruda - As initial treatment for certain advanced urothelial carcinoma patients
05/23/2017 - Merck - Keytruda - Advanced MSI-H or dMMR tumors
07/24/2017 - Bristol-Myers Squibb - Yervoy - Pediatric patients 12yrs+ with metastatic melanoma
08/01/2017 - Bristol-Myers Squibb - Opdivo - Advanced MSI-H or dMMR metastatic colorectal cancer
08/30/2017 - Novartis - Kymriah - Relapsed/Refractory pediatric ALL
09/22/2017 - Merck - Keytruda - Recurrent Locally Advanced or Metastatic Gastric Cancer
09/22/2017 - Bristol-Myers Squibb - Opdivo - Hepatocellular carcinoma after prior sorafenib use
10/18/2017 - Gilead Sciences - Yescarta - Aggressive NHL
12/20/2017 - Bristol - Opdivo - Adjuvant for resected melanoma w/ LN involvment or metastatic disease.
02/16/2018 - Astra - Imfinzi - Stage III unresectable NSCLC after no progression w/ chemoradiation.
03/29/2018 - Amgen - Blincyto - MRD+ B-Cell Precursor ALL In Adults And Children.
04/16/2018 - Bristol - Opdivo+Yervoy - First-line patients w/ intermediate and poor risk advanced RCC.
05/01/2018 - Novartis - Kymriah - relapsed or refractory large B-cell lymphoma.
06/12/2018 - Merck - Keytruda - advanced cervical cancer w/ progression during or after chemo.
06/13/2018 - Merck - Keytruda - refractory primary mediastinal large B-cell lymphoma (PMBCL).
07/11/2018 - Bristol - Opdivo+Yervoy - MSI-H/dMMR mCRC Patients who progress after chemo.
08/17/2018 - Bristol - Opdivo - Advanced SCLC that has progressed after chemo + one line of therapy.
09/28/2018 - Regn/Sny - Libtayo - Advanced Cutaneous Squamous Cell Carcinoma.
10/31/2018 - Merck - Keytruda - In combo with chemo in 1st line metastatic squamous NSCLC.
12/06/2018 - Roche - Tecentriq - In combo with avastin and chemo in metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.
12/19/2018 - Merck - Keytruda - Metastatic Merkel cell carcinoma.
02/19/2019 - Merck - Keytruda - Adjuvant treatment of melanoma with lymph node involvement after complete resection.
03/08/2019 - Roche - Tecentriq - In combo with avastin in inoperable PD-L1 high metastatic TNBC.
03/19/2019 - Roche - Tecentriq - In combo with chemo for the initial treatment of (ES-SCLC).
04/11/2019 - Merck - Keytruda - 1L stage III NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 ≥1% with no EGFR or ALK genomic tumor aberrations.
04/19/2019 - Merck - Keytruda - In combination with Inlyta for 1L advanced RCC.
05/14/2019 - Merck KGaA - Bavencio - In combination with Inlyta for 1L advanced RCC.
06/11/2019 - Merck - Keytruda - 1L advanced HNSCC for patients whose tumors express PD-L1
06/11/2019 - Merck - Keytruda - 1L advanced HNSCC in combo with chemo for all patients.
06/18/2019 - Merck - Keytruda - SCLC mono therapy for patients with progression on or after chemo and at least one other prior line of therapy.
Who Am I?

I'm an individual investor from Kansas City. My focus is on biotech stocks, but I enjoy investing in all industries. I'm an old-school, buy and hold investor who believes the best way to outperform and grow capital is to own innovative companies with good management teams over the long-term. more>>>